MRNS * Stock Overview
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$124.00 |
| 52 Week High | US$214.05 |
| 52 Week Low | US$124.00 |
| Beta | 0.89 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -56.14% |
| 5 Year Change | -64.94% |
| Change since IPO | -80.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRNS * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 4.8% | -0.8% |
| 1Y | n/a | -13.3% | 2.4% |
Return vs Industry: Insufficient data to determine how MRNS * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MRNS * performed against the MX Market.
Price Volatility
| MRNS * volatility | |
|---|---|
| MRNS * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.0% |
Stable Share Price: MRNS * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRNS *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 166 | Scott Braunstein | marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| MRNS * fundamental statistics | |
|---|---|
| Market cap | Mex$1.35b |
| Earnings (TTM) | -Mex$2.40b |
| Revenue (TTM) | Mex$526.39m |
2.6x
P/S Ratio-0.6x
P/E RatioIs MRNS * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNS * income statement (TTM) | |
|---|---|
| Revenue | US$30.99m |
| Cost of Revenue | US$101.32m |
| Gross Profit | -US$70.33m |
| Other Expenses | US$71.07m |
| Earnings | -US$141.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -2.57 |
| Gross Margin | -226.96% |
| Net Profit Margin | -456.31% |
| Debt/Equity Ratio | 649.9% |
How did MRNS * perform over the long term?
See historical performance and comparison